TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04593121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB107
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB107
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB107
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB107
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB107
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB107
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT05257382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ENB followed by trans-bronchial biopsy and trans-bronchial cryobiopsy
Description: After having performed the ENB procedure to reach the identified lung lesion, biopsies will be performed (six forceps trans-bronchial biopsies and one trans-bronchial lung cryobiopsy)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ENB followed by trans-bronchial biopsy and trans-bronchial cryobiopsy
Description: After having performed the ENB procedure to reach the identified lung lesion, biopsies will be performed (six forceps trans-bronchial biopsies and one trans-bronchial lung cryobiopsy)
Study: NCT03848416

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC
Study: NCT03186430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Vaccine Promotion Package
Description: Practice-level components: Periodic feedback on adolescent immunization coverage. Assistance with implementing and utilizing standing orders for adolescent vaccine administration in the practice, utilizing standardized materials as provided by the Centers for Disease Control and Prevention and the Immunization Action Coalition. Identification of an immunization champion to facilitate immunization activities in the practice. Linkage to peer-to-peer training on adolescent vaccination through the Georgia Educating Providers In their Communities (EPIC) program.~Provider-level components: Providers will receive standardized talking points, vaccine promotion scripts and answers to frequently asked questions, with training on how best to discuss, recommend and answer questions about vaccines.~Patient/Parent-level components: An iPad tablet-based educational presentation will be provided for parents while they are waiting with their adolescent child in the examination room.
Study: NCT03103854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BURST physical activity
Description: BURST is a novel exercise regimen consisting of three daily periods of 10 minutes of high intensity physical activity spread throughout the day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BURST physical activity
Description: BURST is a novel exercise regimen consisting of three daily periods of 10 minutes of high intensity physical activity spread throughout the day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Reminders
Description: Patients were sent daily text message reminders to remind them to exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Reminders
Description: Patients were sent daily text message reminders to remind them to exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Intensity Continuous Training
Description: This is the current standard of care for cardiac rehabilitation patients. It consists of 1 daily period of 30 minutes of moderate intensity physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Training
Description: This is the current standard of care for cardiac rehabilitation patients. It consists of 1 daily period of 30 minutes of moderate intensity physical activity.
Study: NCT05508828

Intervention type: PROCEDURE
Intervention: Percutaneous Continuous Irrigation assisted Vacuum Drainage Combined With Transgastric Necrosectomy
Description: All patients with SAP were given contrast enhanced CT scan within 48 hours after admission to identify the location and range of the necrosis. If the patient's condition progressively worsened, a multifunctional irrigation-assisted vacuum drainage tube was placed by the CT-guided Seldinger technique in each of the necrosis cavity. Subsequently, transgastric necrosectomy were performed by one or two experienced endoscopist under conscious sedation. The procedure was repeated until all loosely adherent necrotic material were cleared and replaced by granulation tissue. Percutaneous irrigation was stopped and replace with simple drainage if the patient's condition continues to improved and the cavity confirmed by CT was resolution. If the drainage volume was less than 10 mL/day for 3 consecutive days, clamp the drainage tube and remove it finally.
Study: NCT01639469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured exercise
Description: Structured exercise includes stretching, strengthening, and balance exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle exercise
Description: Subjects will be taught lifestyle exercises and advised about mobility strategies
Study: NCT03256721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib/docetaxel/pemetrexed
Description: Participants are randomly assigned to treatment group or control group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel/pemetrexed
Description: Participants are randomly assigned to treatment group or control group
Study: NCT04150562

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: avelumab (800mg by intravenous (IV) will be administered on days 8 and 22 of the 28- day cycle for four cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: avelumab (800mg by intravenous (IV) will be administered on days 8 and 22 of the 28- day cycle for four cycles
Study: NCT04504630

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Definition Transcranial Direct Current Stimulation
Description: This wireless device delivers a very low electrical current to focused regions on the scalp in order to modulate underlying brain circuits to promote neuroplasticity. The device will be fitted onto a neoprene EEG cap, with 1 anode electrode placed and surrounded by 4 cathode electrodes in a ring pattern. Electrical stimulation will be applied using a constant voltage cortical stimulator (Model D185, Digitimer Ltd, UK, maximal output 1000 V/1.5 A) with single square-wave 50-μs pulses (0.1 A/μs rise time).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham HD-tDCS
Description: Sham HD-tDCS
Study: NCT04316507

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Genetic Counselling and Testing
Description: Oncologist-initiated brief genetic counselling and testing
Study: NCT02700672

Intervention type: OTHER
Intervention: Observational study
Description: Observational study: kinematic variables, falls and executive function were analyzed

Intervention type: OTHER
Intervention: Observational study
Description: Observational study: kinematic variables, falls and executive function were analyzed
Study: NCT03155139

Intervention type: DIAGNOSTIC_TEST
Intervention: Aldosterone/renin ratio (ARR) testing
Description: Plasma aldosterone concentration tests, Direct renin concentration tests

Intervention type: DIAGNOSTIC_TEST
Intervention: Aldosterone/renin ratio (ARR) testing
Description: Plasma aldosterone concentration tests, Direct renin concentration tests

Intervention type: DIAGNOSTIC_TEST
Intervention: Confirmatory tests
Description: Captopril challenge test, Saline infusion test
Study: NCT03888014

Intervention type: DEVICE
Intervention: GLOW800
Description: The treatment group will consist of patients who require a medically necessary craniotomy. If an investigator deems that it will be useful to see blood vessels better with indocyanine green (ICG) videoangiography (VA), patients may be consented for the use if ICG VA using augmented reality (GLOW800). This will not add additional time or risk to their surgery

Intervention type: DRUG
Intervention: indocyanine green (ICG)
Description: This is a standard medication which can be given IV during a surgery to better visualize blood vessels under the microscope
Study: NCT02156193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic clip
Description: Prophylactic clipping

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No prophylactic management
Description: No prophylaxis
Study: NCT01201551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine
Description: Week1, day2: 1 eyedrop/right eye Week2, day1: 1 eyedrop/left eye Week2, day2: 1 eyedrop/left eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine
Description: Week1, day2: 1 eyedrop/right eye Week2, day1: 1 eyedrop/left eye Week2, day2: 1 eyedrop/left eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Week1, day1: 1 eyedrop/right eye Week1, day2: 1 eyedrop/right eye Week2, day2: 1 eyedrop/left eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Week1, day1: 1 eyedrop/right eye Week1, day2: 1 eyedrop/right eye Week2, day2: 1 eyedrop/left eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Week1, day1: 1 eyedrop/left eye Week1, day2: 2 eyedrops/left eye Week2, day1: 1 eyedrop/right eye Week2, day2: 2 eyedrops/right eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Week1, day1: 1 eyedrop/left eye Week1, day2: 2 eyedrops/left eye Week2, day1: 1 eyedrop/right eye Week2, day2: 2 eyedrops/right eye
Study: NCT00112866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo tumor resection
Study: NCT03963713

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Using multimodal image fusion to outline the target area.PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 60-72 when the distance between the tumor and gastrointestinal tract or spinal cord was more than 5 mm (alpha/beta=10) and 51.3-59.5 when the distance between the tumor and gastrointestinal tract or spinal cord was less than 5 mm (alpha/beta=10).
Study: NCT00112866

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo tumor resection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02070497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: case management
Description: case management group will accept the case manager's service; the control group will just accept the routine care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: case management
Description: case management group will accept the case manager's service; the control group will just accept the routine care
Study: NCT03963713

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventionally-fractionated image- guided Intensity modulated radiotherapy
Description: Using multimodal image fusion to outline the target area.The dose of the target volume radiotherapy dose is 30 Gy/10f or 40Gy/20f.Previous treatment and follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control rate and side effects, and to clarify the effectiveness and safety of different doses of radiotherapy.
Study: NCT00112866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00917319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bundling Infection Control Interventions
Description: identify risk factors for developing HAIs, receive general infection control measures as well as infection control measures appropriate for the identified risk factor (s)
Study: NCT02422082

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L. reuteri
Description: Dietary supplementation with L. reuteri twice daily for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dietary supplementation with placebo twice daily for 12 months
Study: NCT04157699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF tablet
Description: TDF tablet 300mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF tablet
Description: TDF tablet 300mg QD
Study: NCT02833701

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Given IV
Study: NCT04157699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF tablet
Description: TDF tablet 300mg QD
Study: NCT04404361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: 100 mg capsules
Study: NCT02833701

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given intravenously (IV)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04404361

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching pacritinib 100 mg capsules
Study: NCT04232995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Balance enhancing exercises
Study: NCT04477915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core exercises
Description: Core stabilization exercise include, plank, lateral plank, swimmer, flutter kick and bridge exercises.
Study: NCT04157699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF tablet
Description: TDF tablet 300mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL-007
Description: QL-007 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL-007
Description: QL-007 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL-007
Description: QL-007 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL-007
Description: QL-007 tablet
Study: NCT02540590

Intervention type: DEVICE
Intervention: laser speckle contrast imaging of the oral mucosa
Description: Non-invasive method to measure tissue blood perfusion applied for oral mucosa

Intervention type: DEVICE
Intervention: laser speckle contrast imaging of the oral mucosa
Description: Non-invasive method to measure tissue blood perfusion applied for oral mucosa

Intervention type: DEVICE
Intervention: wound fluid measurement
Description: Wound fluid at the gingival sulcus was volumetrically measured by Periotron 8000 instrument using filter strip

Intervention type: DEVICE
Intervention: wound fluid measurement
Description: Wound fluid at the gingival sulcus was volumetrically measured by Periotron 8000 instrument using filter strip
Study: NCT02473783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline HCl
Description: The regimen of Sertraline HCl will be administered with starting dose from minimum 25 mg/day for 1 week and maintenance dose of at least 50 mg/day up to 200 mg/day for the rest of 5 weeks.
Study: NCT02011269

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trichuris Suis Ova

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trichuris Suis Ova

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Trichuris Suis Ova
Study: NCT01428219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib is available in capsule form. The dose is 60 mg daily by mouth. Subjects with disease progression at 6 weeks who do not have significant toxicities may remain on therapy for an additional six weeks until a progression is confirmed. Further study drug administration beyond 12 weeks will be at the discretion of the investigator provided that the subject does not have disease progression, does not have unacceptable side effects, does not withdraw from study, or does not have a medical condition or illness that renders the subject unacceptable to receive further study drug.
Study: NCT00533130

Intervention type: PROCEDURE
Intervention: clinical evaluation
Description: analyze the x ray from each patient and evaluate the treatment y development of bone healing.

Intervention type: PROCEDURE
Intervention: observational study
Description: evaluate the walk patron, bone healing and range of motion at 1,3,6,12 months
Study: NCT00783432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astepro Nasal Spray (0.1% azelastine hydrochloride)
Description: 548 mcg (2 sprays per nostril) twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Astelin Nasal Spray (0.1% azelastine hydrochloride)
Description: 548 mcg (2 sprays per nostril) twice a day
Study: NCT01615744

Intervention type: PROCEDURE
Intervention: Open Reduction Internal Fixation
Description: Lateral approach through extensile lateral incision ( Benirschke), Reduction ( Soeur et Remy) and internal fixation with lateral plating with or without bone graft

Intervention type: PROCEDURE
Intervention: Non-surgical management
Description: Early active exercises and elevation to decrease swelling
Study: NCT02102958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DSME with Nonvisual Foot Examination
Description: Diabetes Self-Management Education (DSME) with Nonvisual Foot Examination included comprehensive DSME taught by Certified Diabetes Educators that included instruction in nonvisual self-examination of feet using the senses of touch and smell.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DSME with Usual Foot Examination Instruction
Description: DSME with usual foot examination instruction was comprehensive diabetes self management education taught by Certified Diabetes Educators that included usual care instructions for examination for feet at home by visually impaired persons, i.e., to have a sighted person check the feet regularly.
Study: NCT04884503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam tablets
Description: Dosing of clonazepam was as follows: in the first week, 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning), in the second week, 1 mg to be sucked for 2 minutes, and then swallowed (twice a day in the morning and one hour before falling asleep), in the third week, 1 mg to be sucked for 2 minutes and in the fourth week 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tongue pads
Description: wearing a tongue pad 3 times a day for 20 minutes for 4 weeks
Study: NCT02471053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Exercise
Description: Exercise sessions will be held twice-weekly and will begin with a group warm-up activity, followed by 45 minutes of aerobic activity and ending with a cool down. All aerobic exercise will be performed at a moderate intensity, defined as exercise that elicits a heart rate (HR) between 40-60% of heart rate reserve (HRR). Prior to the initial exercise session target heart rates will be calculated for each subject based on the maximum HR achieved during their baseline stress test.
Study: NCT02473783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I-123-ADAM SPECT
Description: The subjects underwent the SPECT scan after I-123-ADAM (185 MBq, 5mCi) IV injection.
Study: NCT03868462

Intervention type: DEVICE
Group type: OTHER
Intervention: Optos P200TE
Description: The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.

Intervention type: DEVICE
Group type: OTHER
Intervention: Predicate Device
Description: The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.
Study: NCT03918109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-313
Description: single intratympanic injection of gacyclidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single intratympanic injection of placebo
Study: NCT03002662

Intervention type: OTHER
Intervention: colonoscopy

Intervention type: OTHER
Intervention: colonoscopy

Intervention type: OTHER
Intervention: colonoscopy

Intervention type: OTHER
Intervention: colonoscopy
Study: NCT03163004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation of standing desks
Description: Three standing desks will be introduced to the classroom
Study: NCT02802618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive 3D visualization technique
Description: The pulmonary rehabilitation consists of exercise training during two times/week for 10 weeks and a theoretic part presented with 3D visualization technique.